ES3061217T3 - Crystal forms of crisaborole in free form and preparation method and use thereof - Google Patents
Crystal forms of crisaborole in free form and preparation method and use thereofInfo
- Publication number
- ES3061217T3 ES3061217T3 ES17795532T ES17795532T ES3061217T3 ES 3061217 T3 ES3061217 T3 ES 3061217T3 ES 17795532 T ES17795532 T ES 17795532T ES 17795532 T ES17795532 T ES 17795532T ES 3061217 T3 ES3061217 T3 ES 3061217T3
- Authority
- ES
- Spain
- Prior art keywords
- crystalline form
- solvent
- crisaborol
- free
- mixed solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610301832 | 2016-05-09 | ||
| PCT/CN2017/083631 WO2017193914A1 (zh) | 2016-05-09 | 2017-05-09 | 克立硼罗游离形式的晶型及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3061217T3 true ES3061217T3 (en) | 2026-03-31 |
Family
ID=60266671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17795532T Active ES3061217T3 (en) | 2016-05-09 | 2017-05-09 | Crystal forms of crisaborole in free form and preparation method and use thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11773113B2 (https=) |
| EP (1) | EP3456722B1 (https=) |
| JP (3) | JP2019520321A (https=) |
| KR (1) | KR102221472B1 (https=) |
| CN (2) | CN119751489A (https=) |
| AU (1) | AU2017262235C1 (https=) |
| BR (1) | BR112018073017B1 (https=) |
| CA (1) | CA3023851C (https=) |
| ES (1) | ES3061217T3 (https=) |
| IL (1) | IL262878A (https=) |
| MX (1) | MX380022B (https=) |
| SG (1) | SG11201809984PA (https=) |
| WO (1) | WO2017193914A1 (https=) |
| ZA (1) | ZA201807892B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10329311B1 (en) * | 2017-12-21 | 2019-06-25 | Olon S.P.A. | Process for the preparation of crisaborole |
| PL3737685T3 (pl) * | 2018-01-09 | 2023-10-02 | Halcyon Labs Private Limited | Sposób wytwarzania kryzaborolu i jego związków pośrednich |
| US10597410B2 (en) | 2018-02-02 | 2020-03-24 | Dipharma Francis S.R.L. | Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent |
| CN110780005B (zh) * | 2019-11-14 | 2022-07-29 | 江苏海岸药业有限公司 | 一种克立硼罗原料及其合成中间体的分析方法 |
| CN111983123A (zh) * | 2020-08-14 | 2020-11-24 | 江苏海岸药业有限公司 | 用于治疗皮肤疾病的克立硼罗制剂的体外评价方法 |
| CN112375093A (zh) * | 2020-11-13 | 2021-02-19 | 江苏知原药业股份有限公司 | 一种克立硼罗晶型化合物及其制备方法 |
| CN113087733A (zh) * | 2021-04-06 | 2021-07-09 | 南京科默生物医药有限公司 | 克立硼罗的晶型a、晶型b、晶型c、晶型d、晶型e及其制备方法 |
| AR130361A1 (es) * | 2022-09-01 | 2024-11-27 | Guilherme Savoi | Cocristales derivados de crisaborol |
| CN115417890A (zh) * | 2022-09-24 | 2022-12-02 | 中山万远新药研发有限公司 | 克立硼罗的新晶型及其制备方法与用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN191496B (https=) * | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
| GB2383042A (en) * | 2001-10-18 | 2003-06-18 | Cipla Ltd | Amorphous alendronate sodium |
| EP2343304B1 (en) | 2005-02-16 | 2015-06-10 | Anacor Pharmaceuticals, Inc. | Biocidal boronophthalide compounds |
| CN101505603A (zh) * | 2005-12-30 | 2009-08-12 | 安纳考尔医药公司 | 含硼的小分子 |
| KR20080110984A (ko) | 2005-12-30 | 2008-12-22 | 아나코르 파마슈티칼스 인코포레이티드 | 보론함유 소분자 |
| PT1988779E (pt) * | 2006-02-16 | 2015-09-04 | Anacor Pharmaceuticals Inc | Moléculas pequenas contendo boro como agentes antiinflamatórios |
| US20070286822A1 (en) | 2006-06-12 | 2007-12-13 | Anacor Pharmaceuticals Inc. | Compounds for the Treatment of Periodontal Disease |
| RU2008152367A (ru) * | 2006-06-12 | 2010-07-20 | Анакор Фармасьютикалз, Инк. (Us) | Соединения для лечения периодонтального заболевания |
| KR20150065941A (ko) * | 2008-03-06 | 2015-06-15 | 아나코르 파마슈티칼스 인코포레이티드 | 소염제로써 붕소가 함유된 소분자 |
| SG10202112628UA (en) * | 2015-11-30 | 2021-12-30 | Anacor Pharmaceuticals Inc | Topical pharmaceutical formulations for treating inflammatory-related conditions |
| WO2017203514A1 (en) * | 2016-05-26 | 2017-11-30 | Perrigo Api Ltd | Polymorphs of crisaborole and production processes therefor |
-
2017
- 2017-05-09 WO PCT/CN2017/083631 patent/WO2017193914A1/zh not_active Ceased
- 2017-05-09 JP JP2018558377A patent/JP2019520321A/ja not_active Withdrawn
- 2017-05-09 CN CN202411806904.3A patent/CN119751489A/zh active Pending
- 2017-05-09 ES ES17795532T patent/ES3061217T3/es active Active
- 2017-05-09 CN CN201780009362.9A patent/CN108884111A/zh active Pending
- 2017-05-09 SG SG11201809984PA patent/SG11201809984PA/en unknown
- 2017-05-09 AU AU2017262235A patent/AU2017262235C1/en active Active
- 2017-05-09 MX MX2018013742A patent/MX380022B/es unknown
- 2017-05-09 EP EP17795532.5A patent/EP3456722B1/en active Active
- 2017-05-09 KR KR1020187035217A patent/KR102221472B1/ko active Active
- 2017-05-09 CA CA3023851A patent/CA3023851C/en active Active
- 2017-05-09 BR BR112018073017-3A patent/BR112018073017B1/pt active IP Right Grant
- 2017-05-09 US US16/099,839 patent/US11773113B2/en active Active
-
2018
- 2018-11-08 IL IL262878A patent/IL262878A/en unknown
- 2018-11-22 ZA ZA2018/07892A patent/ZA201807892B/en unknown
-
2021
- 2021-06-29 JP JP2021107201A patent/JP2021167327A/ja active Pending
-
2023
- 2023-06-12 JP JP2023096006A patent/JP2023116645A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3456722C0 (en) | 2025-12-10 |
| CN108884111A (zh) | 2018-11-23 |
| KR102221472B1 (ko) | 2021-03-02 |
| SG11201809984PA (en) | 2018-12-28 |
| JP2019520321A (ja) | 2019-07-18 |
| CN119751489A (zh) | 2025-04-04 |
| US11773113B2 (en) | 2023-10-03 |
| EP3456722A4 (en) | 2019-12-18 |
| JP2023116645A (ja) | 2023-08-22 |
| CA3023851C (en) | 2021-01-26 |
| JP2021167327A (ja) | 2021-10-21 |
| EP3456722B1 (en) | 2025-12-10 |
| MX2018013742A (es) | 2019-08-01 |
| AU2017262235B2 (en) | 2019-09-19 |
| RU2018142490A3 (https=) | 2020-06-10 |
| EP3456722A1 (en) | 2019-03-20 |
| NZ748385A (en) | 2022-03-25 |
| NZ786020A (en) | 2025-06-27 |
| ZA201807892B (en) | 2021-06-30 |
| BR112018073017B1 (pt) | 2022-06-14 |
| CA3023851A1 (en) | 2017-11-16 |
| AU2017262235C1 (en) | 2020-08-20 |
| US20230234974A1 (en) | 2023-07-27 |
| WO2017193914A1 (zh) | 2017-11-16 |
| IL262878A (en) | 2018-12-31 |
| BR112018073017A2 (pt) | 2019-02-19 |
| RU2018142490A (ru) | 2020-06-10 |
| AU2017262235A1 (en) | 2018-12-06 |
| KR20190005195A (ko) | 2019-01-15 |
| MX380022B (es) | 2025-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3061217T3 (en) | Crystal forms of crisaborole in free form and preparation method and use thereof | |
| ES3022204T3 (en) | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof | |
| KR20220101145A (ko) | 테르페닐 화합물의 신규 염 | |
| BR102015032466A2 (pt) | formas sólidas de um inibidor de ask1 | |
| ES2806780T3 (es) | Compuestos como antagonistas de CRTH2 y usos de los mismos | |
| KR20230038229A (ko) | 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도 | |
| US10626135B2 (en) | Crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof | |
| WO2022121670A1 (zh) | Tolebrutinib的晶型及其制备方法和用途 | |
| US11447506B2 (en) | Crystal forms of crisaborole in free form and preparation method and use thereof | |
| BR112021014327A2 (pt) | Forma cristalina de derivado de 1,2,3-triazolo[1,5-a]pirazinas, método de preparação da referida forma cristalina, composições farmacêuticas compreendendo a mesma e seu uso | |
| ES2815924T3 (es) | Forma D1 cristalina altamente estable de la sal de monoetanolamina de eltrombopag | |
| ES2978392T3 (es) | Sal de adición del agonista del receptor S1P1 y forma cristalina de la misma, y composición farmacéutica | |
| CN117736176A (zh) | 雄激素受体拮抗剂的可药用盐及其多晶型物、制备方法和用途 | |
| ES2875402T3 (es) | Tosilato de palbociclib | |
| CN105859748B (zh) | 多环化合物钠盐及其多晶型、制备方法及应用 | |
| RU2845248C2 (ru) | Кристаллические формы кризаборола в свободной форме и способ их получения и применения | |
| KR20260027280A (ko) | 박스드로스타트의 결정 형태, 및 이의 제조 방법 및 용도 | |
| HK40126656A (en) | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof | |
| NZ748385B2 (en) | Crystal forms of crisaborole in free form and preparation method and use thereof | |
| TW202543633A (zh) | 喹唑啉酮衍生物的晶型及其製備方法和應用 | |
| CN121712763A (zh) | 一种alk抑制剂的结晶形态 | |
| HK40088128A (en) | Salt of compound and pharmaceutical composition containing salt |